Stupak plays bad cop against pharma

In light of the ancient advice to know your adversary, we present a profile of Rep. Bart Stupak (photo), the Michigan Democrat who's helping lead more than a half-dozen probes of Big Pharma and the FDA. The Wall Street Journal says Stupak's focus on the drug industry is just part of a quest to improve government oversight of consumer products. It may not feel that way to Pfizer (whose Lipitor ads have drawn scrutiny) or Sanofi-Aventis (investigated for a botched study of the antibiotic Ketek) or Schering-Plough and Merck (probed on testing and advertising the cholesterol med Vytorin). Or to the FDA, which gets a Stupak missive at least once a week these days.

Maybe that's because of Stupak's "bad cop" demeanor, which he trots out to great effect during Congressional hearings. Indeed, Stupak once was a state trooper. And even his across-the-aisle colleagues commend his "bulldog approach to things."

Pharma isn't so complimentary, of course. In NJ Biz, PhRMA chief Billy Tauzin (photo) blamed the scrutiny on the fact that 2008 is an election year. And, he says, all this time spent investigating simply takes away from time spent developing and approving new products.

- get more on Stupak in the Wall Street Journal
- see the article in NJ Biz

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.